Improving Treg therapy to manage anti-drug antibodies in hemophilia treatment
Official title: Optimizing precision Treg therapy to control anti-drug antibodies
Funded at Indiana University Indianapolis · NIH-11059632 · Data updated 2026-11-12
This study is looking at a new way to help people with hemophilia by improving a type of therapy that can calm down the immune system's unwanted reactions to certain medications, making treatments safer and more effective for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | June 3, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $299,974 |
| NIH project number | 1R56AI175187-01A1 |
| Project ID | NIH-11059632 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with hemophilia who are undergoing treatment with clotting factor replacement therapies.
✕Less likely to help
Patients who do not have hemophilia or are not receiving biotherapeutic treatments may not benefit from this research.
What this research studies
This research aims to enhance regulatory T cell (Treg) therapies to effectively suppress anti-drug antibody (ADA) responses in patients receiving biotherapeutics, particularly for hemophilia. The approach involves engineering synthetic receptors that can specifically target and suppress unwanted immune responses while minimizing off-target effects. By utilizing a novel synthetic T cell receptor fusion construct (TRuC), the study seeks to improve the efficacy and safety of Treg therapies, which have shown promise in preliminary models. Patients may benefit from a more effective treatment that reduces complications associated with ADA responses.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for hemophilia patients, reducing the risk of adverse immune reactions to necessary therapies.
How similar studies have gone: Previous research has successfully utilized engineered T cell therapies in other contexts, such as CAR T cells for blood cancers, indicating potential for success in this novel application.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Biswas, Moanaro — Indiana University Indianapolis
- Study coordinator: Biswas, Moanaro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.